A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...

Bristol Myers Squibb said a key European regulatory committee is backing a formulation of its blockbuster cancer drug Opdivo that can be injected under the skin.

Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...

Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

The committee based its decision on data showing the subcutaneous formulation of Opdivo was not inferior to the intravenous formulation.

CHMP backs label expansions for BMS's Opdivo, BeiGene's Tevimbra, AstraZeneca's Calquence & others; recommends approval of ...

Visby Medicaltm, a leading innovator in medical diagnostics, announced that the U.S. Food and Drug Administration (FDA) has ...